Investor Presentaiton

Highlights and News Marinomed on the COVID-19 frontline ■ Pre-clinical data show that CarrageloseⓇ has the potential to reduce the risk of an infection with SARS-CoV-2 and may also treat COVID-19 Study in Argentina shows excellent clinical data with CarrageloseⓇ in combination with ivermectin marino med ■ CarrageloseⓇ growth driver for our business - ■ Marinosolv® - platform progress update - first deal for Budesolv expected in H2/20 Record revenues, solid financials and strong outlook for 2020 and beyond 3

View entire presentation